Imagine if AI could understand an
individual’s health based on their data

Vibhor has a breadth of experience in life sciences through his work in industry and academia over the last two decades. Prior to Pangaea, Vibhor started and built the European business for Quantum Secure, which was an enterprise software solutions provider headquartered in Silicon Valley and was successfully acquired by a global corporation in 2015. Following his work at Quantum Secure, Vibhor served as Senior Vice President of Commercial Strategy and Sales at Seven Bridges Genomics, which was founded at Harvard and provided a cloud based bioinformatics platform. Vibhor has also worked as a management and technology consultant for Deloitte. Vibhor’s academic career focused on conducting molecular biology studies and building bioinformatics tools and machine learning models with epigenetic, genomic, transcriptomic and clinical trial data in the context of oncology and infectious diseases. Vibhor has access to an extensive global network in the Life sciences industry and is regularly invited to speak at international conferences, government funded programs and investment summits.

Professor Yike Guo assumed office as the Vice-President (Research and Development) of HKBU on 1 January 2020. Professor Guo is also Professor of Computing Science in the Department of Computing at Imperial College London (2002 – now, on leave since 2020 January). Before joining HKBU, he was the founding Director of the Data Science Institute at Imperial College since 2014, which is one of the six Imperial College Global Challenge Institutes. He is a Fellow of the Royal Academy of Engineering (FREng), Member of Academia Europaea (MAE), Fellow of British Computer Society (FBCS). Professor Guo has published over 250 articles, papers and reports. Projects he has contributed to have been internationally recognized, including winning the “Most Innovative Data Intensive Application Award” at the Supercomputing 2002 conference for Discovery Net, the Bio-IT World “Best Practices Award” for U-BIOPRED in 2014 and the “Best Open Source Software Award” from ACM SIGMM in 2017.

Jingqing is the Head of AI at Pangaea Data Limited. He received his BEng degree in Computer Science and Technology from Tsinghua University, 2016, and MRes degree with distinction in Computing from Imperial College London, 2017. He was awarded National Scholarship of China (top 1%) in 2015. He is the founder and main contributor of some popular deep learning tools including TensorLayer 2.0 and PEGASUS. His projects receive over 8,000 stars on GitHub. Jingqing is also the final year PhD student at Imperial College London with research interest in clinical natural language processing and was a research intern at Google Brain prior to Pangaea.

Dr. Julia Ive is leading NLP research at Pangaea Data Limited. Julia holds a PhD in Machine Translation from LIMSI-CNRS (France). In Pangaea, she is championing deep semantic analysis, the generation of clinical text and privacy-safety of NLP models leading a team of world renown experts. Recently she pioneered the generation of synthetic textual data for biomedical NLP as an innovative solution to the bottleneck data sparsity issue. Julia is also a Research Fellow at the Data Science Institute, Imperial College London. Within her research career, she is working on a range of NLP problems: Machine Translation, Multimodality and Summarisation.

Simon is a qualified accountant with 30 years experience of finance roles in industry, ranging from blue chip multi-nationals to owner managed businesses.
After a grounding at Carlsberg-Tetley, Budweriser and Cadbury, Simon participated in a management buy-out of restaurant group Gaucho.
The last ten years have been spent in software development, firstly of contactless payments within the transport sector at Vix Technology and latterly in digital healthcare with Congenica.
Simon holds an honours degree in Accounting and Management Control and is a Fellow of the Chartered Institute of Management Accountants.

Dr. Musen is Professor of Biomedical Informatics at Stanford University, where he is Director of the Stanford Center for Biomedical Informatics Research. Dr. Musen conducts research related to open science, data stewardship, intelligent systems, and biomedical decision support. His group developed Protégé, the world’s most widely used technology for building and managing terminologies and ontologies. He is principal investigator of the National Center for Biomedical Ontology, one of the original National Centers for Biomedical Computing created by the U.S. National Institutes of Heath (NIH). Dr. Musen chaired the Health Informatics and Modeling Topic Advisory Group for the World Health Organization’s revision of the International Classification of Diseases (ICD-11) and he currently directs the WHO Collaborating Center for Classification, Terminology, and Standards at Stanford University. Early in his career, Dr. Musen received the Young Investigator Award for Research in Medical Knowledge Systems from the American Association of Medical Systems and Informatics and a Young Investigator Award from the National Science Foundation. In 2006, he was recipient of the Donald A. B. Lindberg Award for Innovation in Informatics from the American Medical Informatics Association.

Rick is a 28-year veteran of the pharmaceutical industry, having held senior positions in Clinical Development at Merck & Co. and AstraZeneca. His career has included leading cardiovascular drug development at Merck, and leadership roles in the U.S. Business, Global Medical Sciences, and New Opportunities at AstraZeneca. In 2014 he became a Managing Director in QuintilesIMS (now IQVIA) Consulting Services and then a Senior Vice-President in IQVIA Design & Delivery Innovation, leading the Strategic Drug Development business unit. This unit supports biopharma companies to design integrated development, regulatory, and commercial strategies for their assets, as well as due diligence activities. Rick now is the Managing Director of Pharma Design Solutions, Ltd., his own consultancy practice, supporting senior biopharmaceutical executives with their corporate and organizational aspirations, as well as technology companies interested in improving R&D productivity in the pharmaceutical industry.

Özgür is a senior executive, investor and a strategic advisor in the pharmaceutical industry with over 20 years of experience. Özgür is currently an Investment Partner at Ascension Ventures’s Life Fund which is an investor in Pangaea Data. Most recently, a Global Vice President with IQVIA, he has been overseeing IQVIA’s engagements with world’s leading healthcare investors and boards. In that role, he has been a strategic advisor, involved in over 500 industry shaping M&A, divestment, equity and debt transactions. In addition, he is currently a Board Director in Stablepharma, a UK biotech firm developing thermostable vaccines. Özgür’s pharmaceutical career included leading Pfizer’s portfolio strategy globally for infectious diseases based in New York, USA as well as a Senior Analyst, covering Global Strategic Forecasting for Pharmacia Corporation in New Jersey, USA. Prior to joining IMS Health (IQVIA), Özgür was the Managing Partner of a boutique consulting firm called SARGA Associates with operations in New Jersey, USA and London, UK. He holds an MSc in Management Sciences from the London School of Economics.